Literature DB >> 6993139

"Normal" insulin secretion: the goal of artificial insulin delivery systems?

R P Eaton, R C Allen, D S Schade, J C Standefer.   

Abstract

Prehepatic insulin production can be determined from analysis of connecting-peptide behavior in the plasma. In the present study, we have determined prehepatic insulin production in six normal men throughout a day that included three typical 750-cal meals. Total insulin secretion for the 24 h was 45.4 U, secreted as 10.6 U with breakfast, 13.4 U with lunch, and 13.8 U with dinner. The remaining 7.6 U was secreted during the 9 h night at a rate of 0.85 U/h. At least 50% of the newly secreted insulin is known to be extracted by the liver during the initial transhepatic passage, so that total peripheral delivery can be estimated as approximately 22 U/day. Consequently, portal vein insulin levels are in excess of those seen in peripheral blood by at least 20 +/- 8 microU/ml in the fasted state, and by as much as 115 +/- 15 microU/ml in the 2-h postabsorptive state. The data suggest that insulinization of the liver, without peripheral hyperinsulinemia, may be a goal of artificial insulin delivery.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6993139

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  12 in total

1.  A new drug carrier, Nalpha-deoxycholyl-L: -lysyl-methylester, for enhancing insulin absorption in the intestine.

Authors:  S Lee; J Lee; D Y Lee; S K Kim; Y Lee; Y Byun
Journal:  Diabetologia       Date:  2005-03-01       Impact factor: 10.122

2.  NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue.

Authors:  S Jørgensen; A Vaag; L Langkjaer; P Hougaard; J Markussen
Journal:  BMJ       Date:  1989-08-12

Review 3.  Intranasal insulin. Clinical pharmacokinetics.

Authors:  L Illum; S S Davis
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

Review 4.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

5.  Recombinant DNA derived monomeric insulin analogue: comparison with soluble human insulin in normal subjects.

Authors:  J P Vora; D R Owens; J Dolben; J A Atiea; J D Dean; S Kang; A Burch; J Brange
Journal:  BMJ       Date:  1988-11-12

6.  Treatment of diabetes with insulin. From art to science.

Authors:  M C Riddle
Journal:  West J Med       Date:  1983-06

7.  Importance of early postprandial insulin delivery in insulin-dependent diabetics.

Authors:  W Kerner; H Moll; I Navascués; E F Pfeiffer
Journal:  Klin Wochenschr       Date:  1984-08-01

8.  Quantitative path to deep phenotyping: Possible importance of reduced hepatic insulin degradation to type 2 diabetes mellitus pathogenesis.

Authors:  Richard N Bergman; Francesca Piccinini; Isaac Asare Bediako; Morvarid Kabir; Cathryn Kolka; David Polidori; Marilyn Ader
Journal:  J Diabetes       Date:  2018-07-02       Impact factor: 4.006

9.  Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen.

Authors:  F S Nielsen; L N Jørgensen; M Ipsen; A I Voldsgaard; H H Parving
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

10.  Lipoprotein metabolism in patients with type 1 diabetes under intensive insulin treatment.

Authors:  Alina C R Feitosa; Gilson S Feitosa-Filho; Fatima R Freitas; Bernardo L Wajchenberg; Raul C Maranhão
Journal:  Lipids Health Dis       Date:  2013-02-11       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.